The glomerulopathy of sickle cell disease. Issue 9 (19th June 2014)

• Record Type: Journal Article
• Authors: Ataga, Kenneth I.; Derebail, Vimal K.; Archer, David R.
• Is Part Of: American journal of hematology. Volume 89:Issue 9(2014:Sep.)
• Page Start: 907
• Page End: 914
• Publication Date: 2014-06-19
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23762
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Sickle cell disease (SCD) produces many structural and functional abnormalities in the kidney, including glomerular abnormalities. Albuminuria is the most common manifestation of glomerular damage, with a prevalence between 26 and 68% in adult patients. The pathophysiology of albuminuria in SCD is likely multifactorial, with contributions from hyperfiltration, glomerular hypertension, ischemia‐reperfusion injury, oxidative stress, decreased nitric oxide (NO) bioavailability, and endothelial dysfunction. Although its natural history in SCD remains inadequately defined, albuminuria is associated with increased echocardiography‐derived tricuspid regurgitant jet velocity, systemic blood pressure, and hypertension, as well as history of stroke, suggesting a shared vasculopathic pathophysiology. While most patients with albuminuria are treated with angiotensin converting enzyme inhibitors/angiotensin receptor blockers, there are no published long‐term data on the efficacy of these agents. With the improved patient survival following kidney transplantation, SCD patients with end‐stage renal disease should be considered for this treatment modality. Given the high prevalence of albuminuria and its association with multiple SCD‐related clinical complications, additional studies are needed to answer several clinically important questions in a bid to adequately elucidate its pathophysiology, natural history, and treatment. Am. J. Hematol. 89:907–914, 2014. © 2014 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.</p> </abstract>